Seagen Stock Price, News & Analysis (NASDAQ:SGEN) $215.83 +2.70 (+1.27%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$212.67▼$215.9550-Day Range$211.74▼$217.4552-Week Range$116.08▼$217.51Volume1.42 million shsAverage Volume1.35 million shsMarket Capitalization$40.51 billionP/E RatioN/ADividend YieldN/APrice Target$193.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Seagen MarketRank™ Stock AnalysisAnalyst RatingHold2.35 Rating ScoreUpside/Downside10.6% Downside$193.00 Price TargetShort InterestBearish5.43% of Shares Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.82Based on 12 Articles This WeekInsider TradingSelling Shares$5.98 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.86) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 starsMedical Sector815th out of 949 stocksBiological Products, Except Diagnostic Industry130th out of 149 stocks 1.2 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 6 buy ratings, 11 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $193.00, Seagen has a forecasted downside of 10.6% from its current price of $215.83.Amount of Analyst CoverageSeagen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.43% of the outstanding shares of Seagen have been sold short.Short Interest Ratio / Days to CoverSeagen has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Seagen has recently decreased by 2.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 2.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeagen has received a 2.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Enfortumab vedotin", and "Tucatinib" products. See details.Environmental SustainabilityThe Environmental Impact score for Seagen is -2.55. Previous Next 3.8 News and Social Media Coverage News SentimentSeagen has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Seagen this week, compared to 5 articles on an average week.Search Interest10 people have searched for SGEN on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows3 people have added Seagen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,984,258.00 in company stock.Percentage Held by Insiders25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.86) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 14.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seagen Stock (NASDAQ:SGEN)Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.Read More SGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGEN Stock News HeadlinesDecember 5, 2023 | msn.comSeagen gains amid options trades, optimism for FTC approval for Pfizer dealDecember 3, 2023 | benzinga.comSeagen Stock (NASDAQ:SGEN), Guidance and ForecastDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 2, 2023 | americanbankingnews.comSeagen Inc. (NASDAQ:SGEN) Given Consensus Recommendation of "Hold" by AnalystsDecember 1, 2023 | finance.yahoo.comWhy Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?December 1, 2023 | finance.yahoo.comSeagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority TagNovember 30, 2023 | businesswire.comFDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) for First-Line ...November 30, 2023 | msn.comFDA to decide on approving Keytruda/Padcev combo therapy by May 9December 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 28, 2023 | msn.comPfizer CFO reiterates Seagen closing expected later this year, early next yearNovember 28, 2023 | americanbankingnews.comSeagen Target of Unusually Large Options Trading (NASDAQ:SGEN)November 20, 2023 | benzinga.comIf You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 TodayNovember 15, 2023 | nasdaq.comValidea Detailed Fundamental Analysis - SGENNovember 14, 2023 | finance.yahoo.comSeagen Inc CEO David Epstein Sells Over 10,000 Shares: An Insider Sell AnalysisNovember 10, 2023 | msn.comPfizer may file substantial compliance with FTC on Seagen in 3-4 weeks - CNBCNovember 8, 2023 | morningstar.comSeagen Inc Ordinary SharesNovember 3, 2023 | markets.businessinsider.comSeagen’s Stock Hold Rating: Q3 Earnings Growth, EV-302 Study, and Pending Pfizer DealNovember 3, 2023 | benzinga.comHere's How Much You Would Have Made Owning Seagen Stock In The Last 15 YearsNovember 3, 2023 | finance.yahoo.comSeagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 2, 2023 | businesswire.comNew Data for ADCETRIS ® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30 ...November 2, 2023 | finance.yahoo.comNew Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug ConjugateNovember 1, 2023 | finance.yahoo.comSeagen Inc (SGEN) Reports 33% Increase in 3Q23 Net Product SalesNovember 1, 2023 | benzinga.comLooking At Seagen's Recent Unusual Options ActivityNovember 1, 2023 | finance.yahoo.comSeattle Genetics (SGEN) Reports Q3 Earnings: What Key Metrics Have to SayNovember 1, 2023 | markets.businessinsider.comSeagen Inc Q3 Loss increases, misses estimatesNovember 1, 2023 | finance.yahoo.comSeagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline ProgressOctober 31, 2023 | benzinga.comEarnings Outlook For SeagenSee More Headlines Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Price Target and Rating Average Stock Price Target$193.00 High Stock Price Target$229.00 Low Stock Price Target$129.00 Potential Upside/Downside-10.2%Consensus RatingHold Rating Score (0-4)2.35 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-610,310,000.00 Net Margins-32.61% Pretax Margin-32.12% Return on Equity-28.06% Return on Assets-20.92% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.12 Sales & Book Value Annual Sales$1.96 billion Price / Sales20.57 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book14.24Miscellaneous Outstanding Shares187,700,000Free Float139,084,000Market Cap$40.36 billion OptionableOptionable Beta0.32 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David R. Epstein B.Sc. (Age 61)M.B.A., CEO & Director Comp: $1.39MMr. Todd E. Simpson (Age 62)Chief Financial Officer Comp: $1.26MDr. Vaughn B. Himes Ph.D. (Age 62)Chief Technical Officer Comp: $1.08MMs. Jean I. Liu J.D. (Age 55)M.S., Chief Legal Officer & Corporate Secretary Comp: $1.23MMr. Charles R. Romp (Age 55)Executive Vice President of Commercial U.S. Comp: $1.08MDr. Roger D. Dansey M.D. (Age 67)Chief Medical Officer and President of Research & Development Comp: $2.48MMr. William ComptonSenior VP of Global Information Technology & CIOMr. David CaouetteVice President of Corporate CommunicationsMr. Matt SkeltonVice President of MarketingMs. Peggy M. PinkstonChief Human Resources OfficerMore ExecutivesKey CompetitorsBiogenNASDAQ:BIIBNeurocrine BiosciencesNASDAQ:NBIXGilead SciencesNASDAQ:GILDAmgenNASDAQ:AMGNModernaNASDAQ:MRNAView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 1,736,097 shares on 12/1/2023Ownership: 0.276%American Century Companies Inc.Bought 416 shares on 11/30/2023Ownership: 0.005%Carmignac GestionBought 21,674 shares on 11/29/2023Ownership: 0.020%Decheng Capital Management III Cayman LLCBought 23,014 shares on 11/29/2023Ownership: 0.012%IMA Wealth Inc.Bought 10,348 shares on 11/28/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions Should I Buy Seagen Stock? SGEN Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Seagen was last updated on Tuesday, November 28, 2023 at 9:40 AM. Pros Here are some ways that investors could benefit from investing in Seagen Inc.: Seagen Inc. is a biotechnology company that develops and commercializes therapies for the treatment of cancer. With the increasing prevalence of cancer worldwide, there is a growing demand for innovative and effective cancer treatments. Seagen's ADCETRIS is an antibody-drug conjugate (ADC) that has shown promising results in the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. This product has the potential to address a significant unmet medical need in these patient populations. TUKYSA, an oral small molecule tyrosine kinase inhibitor developed by Seagen, has been approved for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. This product offers a targeted therapy option for a specific subset of breast cancer patients. Seagen has a strong pipeline of potential new therapies in various stages of development. This indicates the company's commitment to innovation and its potential for future growth. The recent insider activity, including the purchase of Seagen's stock by institutional investors and the sale of shares by company insiders, suggests confidence in the company's prospects and may be seen as a positive signal by investors. Cons Investors should be bearish about investing in Seagen Inc. for these reasons: Investing in biotechnology companies carries inherent risks, including the potential for clinical trial failures, regulatory challenges, and competition from other companies in the market. These risks can impact the financial performance and stock price of Seagen Inc. The stock price of Seagen Inc. may be subject to volatility, as it is influenced by various factors such as market conditions, investor sentiment, and news related to the company's products or industry. While Seagen has a strong pipeline, the success of its potential new therapies is not guaranteed. The development and commercialization of new drugs involve significant time, resources, and regulatory approvals, and there is always a risk of failure or delays in the process. The biotechnology industry is highly competitive, with many companies vying for market share and investment. Seagen Inc. faces competition from both established pharmaceutical companies and emerging biotech firms, which could impact its market position and financial performance. Investors should carefully consider their risk tolerance and investment goals before investing in Seagen Inc. It is important to conduct thorough research and seek professional advice to make informed investment decisions. SGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Seagen stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares. View SGEN analyst ratings or view top-rated stocks. What is Seagen's stock price target for 2024? 17 equities research analysts have issued twelve-month target prices for Seagen's stock. Their SGEN share price targets range from $129.00 to $229.00. On average, they anticipate the company's share price to reach $193.00 in the next year. This suggests that the stock has a possible downside of 10.6%. View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts. How have SGEN shares performed in 2023? Seagen's stock was trading at $128.51 at the start of the year. Since then, SGEN shares have increased by 67.9% and is now trading at $215.83. View the best growth stocks for 2023 here. When is Seagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our SGEN earnings forecast. How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The biotechnology company had revenue of $648.65 million for the quarter, compared to the consensus estimate of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. The company's revenue was up 27.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.03) earnings per share. What ETFs hold Seagen's stock? ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), AltShares Event-Driven ET (EVNT), Principal Healthcare Innovators ETF (BTEC) and AltShares Merger Arbitrage ETF (ARB). What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA). Who are Seagen's major shareholders? Seagen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Pentwater Capital Management LP (0.00%), Primecap Management Co. CA (3.34%), Bluefin Capital Management LLC (0.00%), Maven Securities LTD (0.00%), HAP Trading LLC (0.00%) and Barclays PLC (0.94%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David R Epstein, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes. View institutional ownership trends. How do I buy shares of Seagen? Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Seagen have any subsidiaries? The following companies are subsidiares of Seagen: Cascadian Therapeutics.Read More This page (NASDAQ:SGEN) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.